Big Pharma And Biotechs Are Investing More Than $1 Billion In Cancer Research
Scientists are currently developing cutting edge medical advances that may possibly change the way medical care is conveyed.
They are trying to develop ways to treat everything from cancer to Alzheimer’s disease and autoimmune diseases. The new technology could revolutionize how the diseases are treated.
Cancer has become the primary focus of the new technology, called targeted protein degradation or PROTAC. This is in light of the fact that there are some notable drivers of the disease that advanced prescriptions haven’t had the capacity to reach.
According to Business Insider, pharmaceutical companies Novartis, GlaxoSmithKline & Biotech startups alike are investing at least 1 billion dollars in the research hoping for the next big breakthrough. Roughly 30 companies are investing in technology.
Not every one of the rounds of financing around the cutting-edge field has been revealed, so it’s difficult to state precisely what amount is being contributed.
An experimental technology that’s been under development for almost two decades could upend treatment for conditions ranging from Alzheimer’s to lung diseases.
An exploratory innovation that has been a work in progress for approximately two decades could overturn treatment for conditions that range from Alzheimer’s to lung illnesses.
